Metabolic Impact of Adult-Onset, Isolated, Growth Hormone Deficiency (AOiGHD) Due to Destruction of Pituitary Somatotropes
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Growth hormone (GH) inhibits fat accumulation and promotes protein accretion, therefore the fall in GH observed with weight gain and normal aging may contribute to metabolic dysfunction. To directly test this hypothesis a novel mouse model of adult onset-isolated GH deficiency (AOiGHD) was generated by cross breeding rat GH promoter-driven Cre recombinase mice (Cre) with inducible diphtheria toxin receptor mice (iDTR) and treating adult Cre(+/-),iDTR(+/-) offspring with DT to selectively destroy the somatotrope population of the anterior pituitary gland, leading to a reduction in circulating GH and IGF-I levels. DT-treated Cre(-/-),iDTR(+/-) mice were used as GH-intact controls. AOiGHD improved whole body insulin sensitivity in both low-fat and high-fat fed mice. Consistent with improved insulin sensitivity, indirect calorimetry revealed AOiGHD mice preferentially utilized carbohydrates for energy metabolism, as compared to GH-intact controls. In high-fat, but not low-fat fed AOiGHD mice, fat mass increased, hepatic lipids decreased and glucose clearance and insulin output were impaired. These results suggest the age-related decline in GH helps to preserve systemic insulin sensitivity, and in the context of moderate caloric intake, prevents the deterioration in metabolic function. However, in the context of excess caloric intake, low GH leads to impaired insulin output, and thereby could contribute to the development of diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Design and validation of the AOiGHD mouse model. (A) rGHp-Cre and iDTR transgenic mice were crossbred to generate mice that express the DTR in the GH-producing cells (somatotropes) of the anterior pituitary gland, (B) Analysis of DTR mRNA copy number in pituitary (PIT), pancreas (PAN), liver (LIV) and adipose tissue (FAT) from Cre+/−,DTR+/− mice (without DT treatment) reveals that DTR is expressed only in the pituitary (other tissues tested [but not shown] were muscle, spleen, brain, lung, kidney, skin, intestine, adrenal, testis, ovary), “No RT PIT” indicates PCR amplification of total pituitary mRNA which was not reversed transcribed. The tissue specific pattern of DTR mRNA matched that previously reported for Cre recombinase mRNA in rGHp-Cre Tg mice [7]. Cre+/−,DTR+/− mice are normal until treated with DT, which results in the destruction of the somatotrope population. (C) Gross morphology (I) and GH immunofluorescence of pituitary cross-sections (II) and enzymatically dispersed pituitary cells (III) from DT-treated Cre−/−,DTR+/− mice (controls, left panels) and DT-treated Cre+/−,DTR+/− mice (AOiGHD, right panels). GH immuno-positive cells appear red and cell nuclei appear blue (II and III). Somatotropes from DT treated Cre+/−,DTR+/− mice are enlarged, relative to DT treated controls (III arrows). (D) Percentage of GH immuno-positive cells in pituitaries from DT-treated Cre−/−,iDTR+/− mice and vehicle (V)- and DT-treated Cre+/−,DTR+/− mice (left), and pituitary GH mRNA (middle) and circulating GH (right), in DT-treated control and AOiGHD mice. (E) Liver IGF-I mRNA (left) and circulating total IGF-I (right). (F) Hypothalamic expression of GHRH. Analysis of circulating hormones and tissue expression analysis were conducted 7 months post DT treatment. Hormone mRNA copy numbers were adjusted by HPRT mRNA copy number to control for total RNA reverse transcribed and the efficiency of the reaction. (G) Impact of in vitro vehicle- (V) and DT-treatment (10ng/ml for 24h) on GH and prolactin mRNA levels in primary pituitary cell cultures from adult Cre−/−,DTR+/− and Cre+/−,DTR+/− mice, where values are the means of 3 independent experiments. Panels C–F represent data collected after 2 months post-DT treatment with n = 8–12 mice/group. Asterisks indicate values that differ from controls, *, p<0.05, ** p<0.01, and *** p<0.001.](https://figures.cochat.ai/paper-figures/5a7c0f46c7b940be95bb3aa767883e6b/metabolic-impact-of-adult-onset-isolated-growth-hormone-deficiency-aoighd-due-to-figure-1.jpg)
![Figure 2 Impact of 2 to 7 months of AOiGHD on metabolic endpoints in male mice fed a standard rodent chow diet. (A) Body weights (B) Relative fat depot (subcutaneous [SC], urogenital [UG], retroperitoneal [RP]) and liver (LIV) weight, of DT-treated Cre+/−,DTR+/− (AOiGHD) mice compared to DT-treated Cre−/−,DTR+/− controls set at 1. (C) Serum leptin levels measured 2 months post DT treatment in DT-treated Cre−/−,DTR+/− and vehicle-treated Cre+/−,DTR+/− mice (controls [ctrl]), compared to AOiGHD mice. (D) Percent total body weight of free fluid, fat and lean tissue weight measured by whole body NMR 2.5 months post DT treatment, using the MiniSpec LF50 (Bruker Optics, Germany). (E) Insulin tolerance tests (ITT, 0.75U/kg ip) and glucose tolerance tests (GTT, 2g/kg ip) conducted 2–3 months post DT treatment. (F) Glucose and insulin levels measured in serum samples (trunk blood) 7 month post DT treatment. Values are means +/− SEM, of n = 8–12 mice/group. Asterisks indicate values which significantly differ from controls, * p<0.05, *** P<0.001. a, indicates a significant effect of age (p<0.05), independent of GH status. Data presented in panels A–B and E–F are from AOiGHD and littermate controls, where DT was delivered by multiple ip injections, while data shown in panel D is from a separate set of mice (2.5 months post-DT treatment), where DT was delivered by osmotic minipump as described in Fig. 3. It should be noted that these metabolic endpoints did not differ between Cre+/−,DTR+/− and Cre−/−,DTR+/− mice not treated with DT, as shown in Fig. S1.](https://figures.cochat.ai/paper-figures/1839d2f0cc52439282a5f9e4f8fa97e3/metabolic-impact-of-adult-onset-isolated-growth-hormone-deficiency-aoighd-due-to-figure-2.jpg)


![Figure 5 Indirect calorimetry, activity and food/water intake. (A) 48h profiles of respiratory quotient (RQ = VCO2 (ml/min/kg0.75) / VO2 (ml/min/kg0.75) where data was pooled from two separate runs using different mice in each run (n = 10 mice/group total). Comparisons were first made between LF- and HF-fed control mice to verify the accuracy of the gas monitoring system (top panel, 4 months post DT treatment), then AOiGHD mice were compared to controls within diet (LF, 5 months post DT treatment [middle panel] and HF, 5.5 months post DT-treatment [bottom panel]). (B) Percent relative cumulative frequency of 48h RQ values was calculated as reported by Riachi et al [11], and 50th percentile RQ values (values shown adjacent to each curves and demarcated by intercepts of the horizontal solid lines) were compared. (C) Left panels show the mean 48h profiles and right panels show the day and night averages of VO2, VCO2 and energy expenditure (EE, kcal/day/kg0.75) of LF-fed control vs. LF-fed AOiGHD mice conducted in a single run (n = 5 mice/group). (D) Impact of AOiGHD on day and night activity levels. (E) Impact of AOiGHD on 24h ad libitum food and water intake. Asterisks indicate values that differ from controls, *, p<0.05, ** p<0.01, and *** p<0.001.](https://figures.cochat.ai/paper-figures/3f014f4419394a4f9fc2089c52bf781f/metabolic-impact-of-adult-onset-isolated-growth-hormone-deficiency-aoighd-due-to-figure-5.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Altered body composition, insulin resistance, hypertension, unfavorable lipid profile, endothelial dysfunction and atherosclerosis have been found in several studies on patients with long-term GHD (74,76,77,(82)(83)(84)(85)(86)(87).”
From Pituitary Dysfunction After Traumatic Brain Injury: A Clinical and Pathophysiological Approach (2015) · cites this paper as [74]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The pathophysiological mechanism of diabetes and insulin resistance in patients with hypopituitarism is not completely understood; however, available evidence suggests GH as the principal player due to its interaction with many other hormonal and/or peptidic systems (74,91).”
From Pituitary Dysfunction After Traumatic Brain Injury: A Clinical and Pathophysiological Approach (2015) · cites this paper as [74]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypopituitarism, in general, and GHD, in particular, are associated with a number of metabolic alterations (74 -79).”
From Pituitary Dysfunction After Traumatic Brain Injury: A Clinical and Pathophysiological Approach (2015) · cites this paper as [74]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751 · cited 1×
“Liver was homogenized in PBS containing protease inhibitors and an aliquot extracted according to the method of Bligh and Dyer [10].”
Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., & Speleman, F. (2002) · Genome Biology · doi:10.1186/gb-2002-3-7-research0034 · Cited by 20,038 · cited 1×
“3 program [9].”
Giustina, A., & Veldhuis, J. D. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.6.0353 · Cited by 1,253 · cited 1×
“Circulating growth hormone (GH) and insulin-like growth factor I (IGF-I) levels steadily rise after birth, plateau around puberty, then decline thereafter at a rate of ,14% for every decade of life [1].”
A Cre-inducible diphtheria toxin receptor mediates cell lineage ablation after toxin administration
Buch, T., Heppner, F. L., Tertilt, C., Heinen, T. J. A. J., Kremer, M., Wunderlich, F. T., Jung, S., & Waisman, A. (2005) · Nature Methods · doi:10.1038/nmeth762 · Cited by 921 · cited 2×
“At 10wk of age, DT was administered by multiple injections, as originally reported [8].”
Self-citationGiustina, A. (1998) · Endocrine Reviews · doi:10.1210/er.19.6.717 · Cited by 489
Scacchi, M., Pincelli, A., & Cavagnini, F. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800807 · Cited by 316 · cited 4×
“AOiGHD increases fat depot weight but decreases liver weight and TG content As observed in humans with AOGHD [2,45], AOiGHD mice have relatively more fat, compared to GH-intact controls.”
InfluentialBiological effects of growth hormone on carbohydrate and lipid metabolism
Vijayakumar, A., Novosyadlyy, R., Wu, Y., Yakar, S., & LeRoith, D. (2010) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2009.09.002 · Cited by 300 · cited 1×
“Since GH has both lipolytic and anabolic properties [3], it is hypothesized that the decline in GH with age and weight gain is in part responsible for the progression of metabolic disease.”
Luque, R. M., Kineman, R. D., & Tena-Sempere, M. (2007) · Endocrinology · doi:10.1210/en.2007-0500 · Cited by 261 · cited 1×
“3B), as previously reported [13–15].”
Self-citationFan, Y., Menon, R. K., Cohen, P., Hwang, D., Clemens, T., DiGirolamo, D. J., Kopchick, J. J., Le Roith, D., Trucco, M., & Sperling, M. A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.014308 · Cited by 255 · cited 2×
“In the liver-specific GHR knockout mice, lipid accumulation was associated with a decrease in TG secretion [49].”
Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1–deficient mice
Yakar, S., Setser, J., Zhao, H., Stannard, B., Haluzik, M., Glatt, V., Bouxsein, M. L., Kopchick, J. J., & LeRoith, D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci17763 · Cited by 252 · cited 2×
“Our results are consistent with reports showing GH-mediated insulin resistance occurs in liver-specific IGF-I knockout (LID) mice, which have a 75% reduction in circulating IGF-I levels leading to a 3–4 fold increase in GH, with no significant alteration in circulating FFA levels [32].”
Liu, J.-L., Coschigano, K. T., Robertson, K., Lipsett, M., Guo, Y., Kopchick, J. J., Kumar, U., & Liu, Y. L. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00423.2003 · Cited by 218 · cited 1×
“In order for glucose tolerance to remain constant when whole body insulin sensitivity changes, a reciprocal alteration in insulin output has to occur, which is indeed the case in LF-fed AOiGHD mice which show improved insulin sensitivity and low insulin levels under both fed and fasted conditions. However, HF-fed AOiG…”
Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1–deficient mice
Yakar, S., Setser, J., Zhao, H., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200417763 · Cited by 201
Cui, Y., Hosui, A., Sun, R., Shen, K., Gavrilova, O., Chen, W., Cam, M. C., Gao, B., Robinson, G. W., & Hennighausen, L. (2007) · Hepatology · doi:10.1002/hep.21713 · Cited by 183 · cited 3×
“The reduction in hepatic TG content in HF - fed AOiGHD mice at first appears in conflict with the reports showing hepatosteatosis develops in mice with liver - specific knockout of STAT5b [ 48 ] , a key mediator of hepatic GH actions , and in mice with liver - specific knockout of GHR [ 49 ] .”
Dominici, F., Hauck, S., Argentino, D., Bartke, A., & Turyn, D. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1730081 · Cited by 176 · cited 1×
“These studies reveal AOiGHD is associated with both positive and negative effects on metabolic function depending on age and diet. Common across age and diet was the observation that AOiGHD improved whole body insulin sensitivity. These findings are consistent with the improved insulin sensitivity reported in developm…”
del Rincon, J.-P., Iida, K., Gaylinn, B. D., McCurdy, C. E., Leitner, J. W., Barbour, L. A., Kopchick, J. J., Friedman, J. E., Draznin, B., & Thorner, M. O. (2007) · Diabetes · doi:10.2337/db06-0299 · Cited by 164
Luque, R. M., & Kineman, R. D. (2006) · Endocrinology · doi:10.1210/en.2005-1549 · Cited by 155
Self-citationModulation of GH/IGF-1 axis: Potential strategies to counteract sarcopenia in older adults
Giovannini, S., Marzetti, E., Borst, S. E., & Leeuwenburgh, C. (2008) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2008.08.001 · Cited by 136 · cited 1×
“Therefore, multiple studies have been conducted to examine the impact of GH replacement in elderly and obese individuals [4–6] and off-label use and abuse of GH is becoming more prevalent in healthy adults to enhance body image and athletic performance.”
Acutely reduced locomotor activity is a major contributor to Western diet-induced obesity in mice
Bjursell, M., Gerdin, A.-K., Lelliott, C. J., Egecioglu, E., Elmgren, A., Törnell, J., Oscarsson, J., & Bohlooly-Y, M. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00401.2007 · Cited by 133 · cited 1×
“S4), as previously reported by other laboratories [17,18].”
Mauras, N., O’Brien, K. O., Welch, S., Rini, A., Helgeson, K., Vieira, N. E., & Yergey, A. L. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.4.6541 · Cited by 115 · cited 1×
“A negative relationship between GH and carbohydrate utilization has also been observed in GH-treated, healthy or GHD subjects [35,36].”
Rosenfalck, A. M. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.11.4173 · Cited by 115 · cited 1×
“Specifically, GHD patients display impaired 1 phase insulin release during a hyperglycemic clamp [45] and 30 months of low dose GH replacement improved insulin output in response to oral GTT 3-fold compared to the pre-GH response [46].”
Growth Hormone is a Growth Factor for the Differentiated Pancreatic β-Cell
Nielsen, J. H., Linde, S., Welinder, B. S., Billestrup, N., & Madsen, O. D. (1989) · Molecular Endocrinology · doi:10.1210/mend-3-1-165 · Cited by 114 · cited 1×
“A direct stimulatory effect of GH on ßcell function is further supported by the observations that islets do express GHR [41,42] and GH stimulates ß–cell proliferation and insulin release in normal human islet cultures [43] and protects against inflammatory cytokine-induced apoptosis in ß-cell lines, where these action…”
Growth Hormone and Glucose Homeostasis
Jørgensen, J. O. L., Krag, M. B., Jessen, N., Nørrelund, H., Vestergaard, E. T., Møller, N., & Christiansen, J. S. (2004) · Hormone Research in Paediatrics · doi:10.1159/000080499 · Cited by 108
Early Postnatal Nutrition Determines Somatotropic Function in Mice
Kappeler, L., De Magalhaes Filho, C., Leneuve, P., Xu, J., Brunel, N., Chatziantoniou, C., Le Bouc, Y., & Holzenberger, M. (2009) · Endocrinology · doi:10.1210/en.2008-0981 · Cited by 88 · cited 1×
“Specifically, all experimental mice were generated by breeding female rGHpCre mice to male iDTR mice and litter size was standardized to 6–8 pups/litter 72h after parturition, based on evidence that early nutritional status can dramatically impact adult metabolic and GH-axis function [12].”
Luque, R. M., Park, S., & Kineman, R. D. (2006) · Endocrinology · doi:10.1210/en.2006-0592 · Cited by 88
Self-citationMenezes Oliveira, J. L., Marques-Santos, C., Barreto-Filho, J. A., Ximenes Filho, R., de Oliveira Britto, A. V., Oliveira Souza, A. H., Prado, C. M., Pereira Oliveira, C. R., Pereira, R. M. C., de Almeida Ribeiro Vicente, T., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2571 · Cited by 88
Enhancement of muscle mitochondrial function by growth hormone
Short, K. R., Moller, N., Bigelow, M. L., Coenen-Schimke, J., & Nair, K. S. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1814 · Cited by 80 · cited 1×
“A negative relationship between GH and carbohydrate utilization has also been observed in GH-treated, healthy or GHD subjects [35,36].”
Yuen, K. C. J., & Dunger, D. B. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00591.x · Cited by 78 · cited 1×
“Improved insulin signaling in the context of isolated GHD is consistent with the well accepted anti-insulin actions of GH following an acute bolus injection in normal and GHD adults [29], and as observed following chronic GH elevation in patients with GH producing pituitary tumors [30], as well as in mice overexpressi…”
Impact of Androgens, Growth Hormone, and IGF-I on Bone and Muscle in Male Mice During Puberty
Venken, K., Movérare-Skrtic, S., Kopchick, J. J., Coschigano, K. T., Ohlsson, C., Boonen, S., Bouillon, R., & Vanderschueren, D. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060911 · Cited by 77 · cited 1×
“Since mice continue to grow after puberty (albeit at a slower rate), the differences observed in the HF-fed groups may be related to the combined effects of low GH and testosterone in AOiGHD mice, where both hormones are required for optimal skeletal and muscle growth [16].”
Luque, R. M., Amargo, G., Ishii, S., Lobe, C. G., Franks, R. R., Kiyokawa, H., & Kineman, R. D. (2007) · Endocrinology · doi:10.1210/en.2006-1542 · Cited by 73 · cited 8×
“(A) rGHp-Cre and iDTR transgenic mice were crossbred to generate mice that express the DTR in the GH-producing cells (somatotropes) of the anterior pituitary gland, (B) Analysis of DTR mRNA copy number in pituitary (PIT), pancreas (PAN), liver (LIV) and adipose tissue (FAT) from Cre +/2 ,DTR +/2 mice (without DT treat…”
InfluentialSelf-citationDiet‐induced obesity and cardiovascular regulation in C57BL/6J mice
Williams, T., Chambers, J., Roberts, L., Henderson, R., & Overton, J. (2003) · Clinical and Experimental Pharmacology and Physiology · doi:10.1046/j.1440-1681.2003.t01-1-03808.x · Cited by 70 · cited 1×
“S4), as previously reported by other laboratories [17,18].”
Vasoactive Intestinal Peptide Is Critical for Circadian Regulation of Glucocorticoids
Loh, D. H., Abad, C., Colwell, C. S., & Waschek, J. A. (2008) · Neuroendocrinology · doi:10.1159/000140676 · Cited by 69 · cited 1×
“The limited impact of GHD in the post-absorptive state may be related to the dramatic diurnal patterns in adrenal function reported in mice, where glucocorticoids levels peak at the end of the light phase [38], which may mask any impact of GHD on peripheral insulin sensitivity.”
Expression of the growth hormone receptor gene in human digestive tissue
Delehaye, M. C., Mertani, H. C., Martini, J.-F., Nihoul‐Feketé, C., Morel, G., & Postel-Vinay, M. C. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.78.6.8200952 · Cited by 68 · cited 12×
“In the liver - specific GHR knockout mice , lipid accumulation was associated with a decrease in TG secretion [ 49 ] .”
InfluentialRiachi, M., Himms-Hagen, J., & Harper, M.-E. (2004) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y04-117 · Cited by 68 · cited 3×
“(B) Percent relative cumulative frequency of 48h RQ values was calculated as reported by Riachi et al [11], and 50 percentile RQ values (values shown adjacent to each curves and demarcated by intercepts of the horizontal solid lines) were compared.”
InfluentialSegerlantz, M. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.12.5813 · Cited by 61 · cited 1×
“This hypothesis is supported by the observation that the anti-insulin actions of short-term GH treatment are blunted by the anti-lipolytic agent, acipimox [31].”
Guo, Y., Lu, Y., Houle, D., Robertson, K., Tang, Z., Kopchick, J. J., Liu, Y. L., & Liu, J.-L. (2005) · Endocrinology · doi:10.1210/en.2004-1203 · Cited by 60
Mauras, N. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.4.1686 · Cited by 57
Visceral obesity, impaired glucose tolerance, metabolic syndrome, and growth hormone therapy
Attallah, H., Friedlander, A. L., & Hoffman, A. R. (2006) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2006.03.004 · Cited by 56 · cited 1×
“Therefore, multiple studies have been conducted to examine the impact of GH replacement in elderly and obese individuals [4–6] and off-label use and abuse of GH is becoming more prevalent in healthy adults to enhance body image and athletic performance.”
Macario, E. (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s3247 · Cited by 55 · cited 1×
“Therefore, multiple studies have been conducted to examine the impact of GH replacement in elderly and obese individuals [4–6] and off-label use and abuse of GH is becoming more prevalent in healthy adults to enhance body image and athletic performance.”
Regulation of pancreatic β-cell mass and proliferation by SOCS-3
Lindberg, K., Rønn, S. G., Tornehave, D., Richter, H., Hansen, J. A., Rømer, J., Jackerott, M., & Billestrup, N. (2005) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.01840 · Cited by 55 · cited 1×
“These observations strongly suggest GH/IGF-I is important in maintaining ß-cell function in the adult, a role only previously recognized in mouse models of developmental global and pancreatic GH insensitivity [20,39,40].”
Long-term growth hormone excess induces marked alterations in lipoprotein metabolism in mice
Frick, F., Bohlooly-Y, M., Lindén, D., Olsson, B., Törnell, J., Edén, S., & Oscarsson, J. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.6.e1230 · Cited by 55 · cited 1×
“This hypothesis is supported by the observation that bGH transgenic mice are also insulin resistant and show reduced hepatic TG secretion [50].”
Vascular Insulin-Like Growth Factor-I Resistance and Diet-Induced Obesity
Imrie, H., Abbas, A., Viswambharan, H., Rajwani, A., Cubbon, R. M., Gage, M., Kahn, M., Ezzat, V., Duncan, E. R., Grant, P. J., et al. (2009) · Endocrinology · doi:10.1210/en.2008-1641 · Cited by 54 · cited 1×
“3B), as previously reported [13–15].”
Kanety, H., Hemi, R., Ginsberg, S., Pariente, C., Yissachar, E., Barhod, E., Funahashi, T., & Laron, Z. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0419 · Cited by 53 · cited 1×
“In addition adult patients with Laron syndrome (inactivating mutations in the GH receptor) remained relatively insulin sensitive (calculated by HOMA-IR), despite an obese phenotype [27].”
Jensen, J., Galsgaard, E. D., Karlsen, A. E., Lee, Y. C., & Nielsen, J. H. (2005) · Journal of Endocrinology · doi:10.1677/joe.1.06086 · Cited by 40 · cited 1×
“A direct stimulatory effect of GH on ßcell function is further supported by the observations that islets do express GHR [41,42] and GH stimulates ß–cell proliferation and insulin release in normal human islet cultures [43] and protects against inflammatory cytokine-induced apoptosis in ß-cell lines, where these action…”
Segerlantz, M., Bramnert, M., Manhem, P., Laurila, E., & Groop, L. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1490511 · Cited by 36 · cited 1×
“Improved insulin signaling in the context of isolated GHD is consistent with the well accepted anti-insulin actions of GH following an acute bolus injection in normal and GHD adults [29], and as observed following chronic GH elevation in patients with GH producing pituitary tumors [30], as well as in mice overexpressi…”
Pereira, R. M. C., Aguiar-Oliveira, M. H., Sagazio, A., Oliveira, C. R. P., Oliveira, F. T., Campos, V. C., Farias, C. T., Vicente, T. A. R., Gois, M. B., Oliveira, J. L. M., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0092 · Cited by 35 · cited 1×
“counterparts [25,26].”
Yuen, K. C. J., & Dunger, D. B. (2006) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2006.03.001 · Cited by 34 · cited 4×
“AOiGHD increases fat depot weight but decreases liver weight and TG content As observed in humans with AOGHD [2,45], AOiGHD mice have relatively more fat, compared to GH-intact controls.”
InfluentialSasaki-Suzuki, N., Arai, K., Ogata, T., Kasahara, K., Sakoda, H., Chida, K., Asano, T., Pessin, J. E., Hakuno, F., & Takahashi, S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808282200 · Cited by 33 · cited 1×
“In vitro studies also support a direct inhibitory effect of GH on insulin signaling in adipocytes [21,34].”
Plasma Glucagon and Insulin Concentrations in Acromegaly
Trimble, E. R., Atkinson, A. B., Buchanan, K. D., & Hadden, D. R. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-51-3-626 · Cited by 28 · cited 1×
“Consistent with these observations, non-diabetic acromegalics were shown to have an exaggerated insulin response to glucose stimulation [47].”
Boyle, P. J., Avogaro, A., Smith, I., SHAH, S. D., Cryer, P. E., & Santiago, J. V. (1992) · Diabetologia · doi:10.1007/bf00401205 · Cited by 27 · cited 1×
“Finally, a lipid-independent effect of GH on insulin signaling is suggested by a clinical study showing GH-treatment of GHD, type I diabetics suppressed insulin sensitivity in the presence or absence of heparin infusion [33].”
Acute Hepatitis A Infection in Hepatitis B Chimpanzee Carriers†
TSIQUAYE, K. N., Harrison, T. J., Portmann, B., Hu, S., & Zuckerman, A. J. (1984) · Hepatology · doi:10.1002/hep.1840040325 · Cited by 26
Metabolic abnormalities in growth hormone deficiency.
Lanes, R. (2004) · PubMed · Cited by 23
Insulin Sensitivity in Adults with Growth Hormone Deficiency and Effect of Growth Hormone Treatment
Groop, L., Segerlantz, M., & Bramnert, M. (2005) · Hormone Research in Paediatrics · doi:10.1159/000089317 · Cited by 20 · cited 1×
“These findings are consistent with the improved insulin sensitivity reported in developmental GHD and GH insensitive (GHRKO) mice [19– 21], but are in contrast to the majority of clinical studies showing adults with GHD are insulin resistant [22–24].”
Phakdeekitcharoen, B., Phudhichareonrat, S., Pookarnjanamorakot, C., Kijkunasathian, C., Tubtong, N., Kittikanokrat, W., & Radinahamed, P. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0552 · Cited by 18
Christ, E., Simpson, H., Breen, L., Sönksen, P. H., Russell-Jones, D. L., & KOHNER, E. M. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01714.x · Cited by 13 · cited 1×
“events, and these features were normalized after GH therapy [28].”
Expression of the growth hormone receptor gene in insulin producing cells.
Nielsen, J. H., Møldrup, A., & Billestrup, N. (1990) · PubMed · Cited by 8
Cited by
Brain metabolic dysfunction at the core of Alzheimer's disease
de la Monte, S. M., & Tong, M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.012 · Cited by 461
“Since growth hormone deficiency promotes obesity [102], and obesity promotes insulin resistance and hyperinsulinemia, agingassociated declines in growth hormone could mediate their effects by causing insulin resistance [103].”
BackgroundThe GH/IGF-1 axis in obesity: pathophysiology and therapeutic considerations
Berryman, D. E., Glad, C. A. M., List, E. O., & Johannsson, G. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.64 · Cited by 229
Pituitary Dysfunction After Traumatic Brain Injury: A Clinical and Pathophysiological Approach
Tanriverdi, F., Schneider, H. J., Aimaretti, G., Masel, B. E., Casanueva, F. F., & Kelestimur, F. (2015) · Endocrine Reviews · doi:10.1210/er.2014-1065 · Cited by 218
The effects of growth hormone on adipose tissue: old observations, new mechanisms
Kopchick, J. J., Berryman, D. E., Puri, V., Lee, K. Y., & Jorgensen, J. O. L. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0280-9 · Cited by 185
The intricate role of growth hormone in metabolism
Vijayakumar, A., Yakar, S., & LeRoith, D. (2011) · Frontiers in Endocrinology · doi:10.3389/fendo.2011.00032 · Cited by 179
“GH secretion occurs in a pulsatile manner that is primarily regulated by the 180˚ out-of-phase secretion of two neuroendocrine hormones from the hypothalamus, namely, the GH releasing hormone (GHRH) and somatostatin that stimulate and repress GH secretion respectively.”
Background
Metadata
- Authors
- Luque, R. M., Lin, Q., Córdoba-Chacón, J., Subbaiah, P. V., Buch, T., Waisman, A., Vankelecom, H., & Kineman, R. D.
- Affiliations
- University of Illinois Chicago (US)
- University Hospital Zurich (CH)
- Johannes Gutenberg University Mainz (DE)
- KU Leuven (BE)
- Corresponding author
- Kineman, Rhonda D.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-01-19
- Volume
- 6
- Issue
- 1
- Pages
- e15767
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3023710
- OpenAlex
- W2002684589
- Semantic Scholar
- 75f044e1b35e0ed4cc5f7c5f7213edfaa8d8df75
- Cited by
- 73
- References
- 54
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 1 · 2022: 2 · 2021: 6 · 2020: 4 · 2019: 3 · 2018: 5 · 2017: 4 · 2016: 8 · 2015: 5 · 2014: 9 · 2013: 7 · 2012: 9
- FWCI
- 7.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Lirias (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Universidad de Córdoba Insitutional Repository (Universidad de Córdoba) (submittedVersion, cc-by-nc-nd)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Funders
- U.S. Department of Veterans Affairs
- Office of Research and Development
- Vlaamse regering
- National Institutes of Health
- Instituto de Salud Carlos III (FI06/00804)
- National Institute on Aging (R21AG031465, AG031465)
- National Heart, Lung, and Blood Institute (R01HL068585, HL68585, R56HL068585)
- National Institute of Diabetes and Digestive and Kidney Diseases (R21DK078165, DK78165, R01DK088133)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- growth hormone, insulin sensitivity, high-fat diet, energy metabolism, fat mass, liver lipids, glucose clearance, diabetes mellitus, aging, mouse model, Cre-loxP system, diphtheria toxin receptor, insulin-like growth factor I
- MeSH terms
- Animals, Energy Intake, Diet, Disease Models, Animal, Energy Metabolism, Insulin Resistance, Insulin-Like Growth Factor I, Mice, Mutant Strains, Pituitary Gland, Anterior, Growth Hormone, Age of Onset, Intercellular Signaling Peptides and Proteins, Carbohydrate Metabolism, Mice, Rats, Somatotrophs, Heparin-binding EGF-like Growth Factor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.